Plus Therapeutics

08/22/2025

We are now a Director of Clinical Development as a hybrid role in either Houston, TX, or Charlottesville, VA.

Job posting: https://indeedhi.re/4n0zd4J

If you are interested in joining our team, please email a cover letter & resume to HR@PlusTherapeutics.com

08/20/2025

Last week, the & CNSide Diagnostics leadership teams met on site at the conference. Both teams' collaboratively sponsored (LM) presentation and panel discussion was the most attended ISS symposium of the event!

Alongside this presentation/panel, and Priya Kumthekar’s FORESEE poster received first place. Leadership from both teams also took several meetings with KOLs and patient advocacy groups onsite.

Request a recording of the symposium here: bit.ly/47DUdtn

American Society of Clinical Oncology ( ), American Brain Tumor Association, Leptomeningeal Cancer Foundation

08/19/2025

Although it’s challenging to quantify the rate of leptomeningeal spread in various cancers, some studies have shown that LM may occur in approximately 9 to 25% of advanced small cell and non-small cell lung cancer.

That’s anywhere from 1 in 11 to 1 in 4 people with advanced lung cancer.

Know the symptoms, know what diagnostic tests to get and if you’ve already been diagnosed, know the treatment options and clinical trials available.

Join us on Thursday, August 21st at 11am PDT / 2pm EDT. Register here to learn from the experts and ask your questions.

http://bit.ly/3J0f6EV

08/18/2025

announces positive data from the ReSPECT-LM Phase 1 single dose escalation presented at the podium at the Society of / American Society of Clinical Oncology Metastases Conference in Baltimore, MD. The data demonstrated treatment of (LM) with is feasible, has a manageable safety profile, and shows a promising efficacy signal.

Read the full press release here: https://bit.ly/4mMesJO

Learn more about the ReSPECT-LM clinical trial here: https://bit.ly/45OBc6O

08/14/2025

announced positive data from a retrospective analysis of the Cerebrospinal Fluid (CSF) Assay Platform at the 2025 ( ) / American Society of Clinical Oncology ( ) Metastases Conference in Baltimore, Maryland.

The data demonstrates that CNSide® can quantify (LM) over time and monitor changes in the expression of multiple targetable mutations. Further, it also may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biology, and enable personalized .

Read more in our press release: https://bit.ly/47rhWgf

CNSide Diagnostics

08/12/2025

Several of the top experts in (LM) are joining a presentation and panel discussion at the ( ) / Society for Neuro-Oncology, USA ( ) Metastases Conference in Baltimore on August 14 at 6:15 PM.

Learn more about the presentation here: https://bit.ly/46MiNbj

Presented by and CNSide Diagnostics

08/07/2025

One of ' Principal Investigators for the clinical trial, Andrew Brenner, M.D., Ph.D., recently spoke to Stephania Jimenez of KSAT 12 & KSAT.com in San Antonio about ( ) and why our trial is promising for patients.

Check out the article and news clip here: https://bit.ly/3H18Egr

The team is continuing to actively recruit patients for the ongoing RESPECT-GBM Phase 2 . Please visit the website if you or someone you know may be eligible: respect-trials.com/gbm or email us at respect@plustherapeutics.com.

, , UT Health San Antonio, Mays Cancer Center at UT Health San Antonio

On the latest episode of "The Conversation," KSAT’s Stephania Jimenez spoke with a local doctor about glioblastoma and a promising new clinical trial for patients.

08/05/2025

Mark your calendars: Join us at the upcoming 2025 SNO/ASCO CNS Metastases Conference in Baltimore, Maryland on Thursday, August 14 at 6:15 PM for a presentation and panel discussion from some of the leading experts in Leptomeningeal Metastases.

This symposium will explore emerging strategies to improve the detection, monitoring, and management of LM. Experts will share real-world evidence, clinical trial updates, evolving perspectives, and what the future may look like for LM diagnostics and radiotherapeutics.

For more information, to register to attend, or to request a recording of the symposium, please visit: https://bit.ly/45jhdv8

Supported by Plus Therapeutics and CNSide Diagnostics

The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Independent Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO/ASCO CNS Metastases Conference program.

08/01/2025

Today is , an annual moment to observe and raise awareness for patients, survivors, and the ongoing need for more research funding.

is currently undergoing a for (LM), which can affect lung cancer patients. Healthcare providers estimate between 4% and 7% of all people who have NSCLC will develop leptomeningeal metastases, and about 11% of people who have SCLC will develop LMD.

Learn more about the ReSPECT-LM trial here: www.respect-trials.com/lm

LUNGevity Foundation, LiveLung, Lung Cancer Research Foundation, Leptomeningeal Cancer Foundation



Source: https://cle.clinic/45kVrXX

07/31/2025

announces that its wholly-owned subsidiary, CNSide Diagnostics, LLC (“CNSide”), will make cerebrospinal fluid (CSF) assay platform and testing services commercially available in Texas in August 2025.

Initial commercial focus will be on National Cancer Institute (NCI) Designated Cancer Centers, which treat the highest number of patients at risk for (LM) and previously used CNSide. These institutions and provider networks include the UT Southwestern Medical Center, MD Anderson Cancer Center, Mays Cancer Center at UT Health San Antonio, Baylor Scott & White Health, and Texas Oncology. The company plans to expand testing services and broaden regional availability over the next 12 months.

Read the full press release here: https://bit.ly/4lp2bKp

07/30/2025

Drug Development & Delivery recently interviewed ' President and CEO, Marc Hedrick, M.D., to discuss our team’s targeted platform for and cancers.

Dr. Hedrick also covered how ’s internal offers patients a more advanced drug delivery solution compared to traditional external radiation therapy.

Read the full Q&A article here: bit.ly/3H70SBB

Learn more about the RESPECT discussed in the article here: www.respect-trials.com

Dr. Marc Hedrick, CEO of Plus Therapeutics, discusses the company’s targeted radiotherapeutic platform for central nervous system and solid tumor cancers and why internal radiation therapy offers patients a more advanced drug delivery solution compared to traditional external radiation therapy.

07/29/2025

’ ongoing ReSPECT-LM dose-optimization for in patients with (LM) aims to refine treatment regimens for the challenging central nervous system ( ) complication.

Check out Sabrina Serani’s recent article in Targeted Oncology, which covers the trial and includes a quote from ’s President and CEO, Marc Hedrick, M.D.

Full article linked here: bit.ly/4ocOJeS

Learn more about the clinical trial here: bit.ly/45OBc6O

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.